sions and by patients swishing 10 mL of normal saline and spitting. One hundred microliters of swish solution was plated on media with or without fluconazole and incubated at 30ЊC for 48 hours before growth was assessed. Three to five colonies from each sample were submitted for determination of MICs by a macrobroth method according to a standard of the National Committee for Clinical Laboratory Standards (NCCLS) [11] to correlate with appearance on fluconazole-containing media as either susceptible or resistant. CHROMagar Candida medium (CHROMagar Company, Paris) with fluconazole was used to improve detection of non -albicans species and resistant isolates [10, 12] . Resistance was defined as an MIC of §16 mg/mL by the NCCLS macrobroth method.
Clinical evaluation was performed by the same health provider. Therapy consisted of fluconazole tablets (200 mg on the first day and 100 mg for 6 days) and was continued until complete resolution of symptoms and oral lesions (clinical re- logical response was defined as sterile cultures at the end of treatment.
The x 2 test (Epi-Info Version 6, Centers for Disease Control and Prevention, Atlanta) and Student's t-test (Microsoft Excel §64 mg/mL. In addition, microbiological responses were seen almost exclusively in episodes where the maximal MIC was 5.0, Microsoft, Redmond, WA) were used where needed.
õ8 mg/mL, even though in episodes with MICs of £1 mg/mL, the rate of microbiological response was only 50%.
Results
The issue of whether a microbiological response affects the time to relapse was assessed in 90 episodes with documented Sixty-four HIV-infected patients presenting with OPC were enrolled in a longitudinal study. fewer reports of failure of high doses of fluconazole. Episodes requiring §200 mg of fluconazole/d for resolution were quite common, seen in 57 (37%) of 155 episodes. Since Discussion fluconazole is very well tolerated, use of high doses appears reasonable and is more efficacious in the treatment of epiTherapy for OPC in HIV-infected patients has become simple and highly effective since the introduction of fluconazole.
sodes with resistant isolates. However, the use of an itraconazole solution is another option for patients for whom high As a result, fluconazole has been widely used for both intermittent therapy and prophylaxis for OPC [2, 3] . Recently, yeast doses of fluconazole have failed, as not all isolates are crossresistant [19] . isolates with decreased susceptibility to fluconazole have been an increasing problem in the treatment of OPC in HIV-infected
Patients from whom resistant isolates (C. albicans or nonalbicans species) were recovered were more likely to require patients, especially that due to C. albicans, although nonalbicans species are also frequently isolated [5, 7, 10, 13, 14] .
higher doses of fluconazole and require longer courses of treatment than were patients from whom only susceptible isolates Clinical resistance due to these isolates has been the subject of several reports [9, 10, 15 -17] . We analyzed our experience were recovered. However, clinical response to 100 mg of fluconazole/d was seen in 22% of episodes with yeast isolates for with 155 well-documented episodes of OPC in HIV-infected patients in a prospective study.
which MICs were §64 mg/mL. In these episodes, the predominant isolates were susceptible and more likely responsible for Antifungal susceptibility testing is an important issue in considering fluconazole resistance in Candida species and has been the clinical response. It is interesting that there was no significant difference in the dose or duration of therapy required when difficult to standardize, although NCCLS guidelines have been approved for standard yeast susceptibility testing [11] . Correlacomparing episodes with either resistant C. albicans or resistant non -albicans species (with susceptible C. albicans) alone in tion between in vitro susceptibility and clinical response has been the focus of much investigation, which suggests that in culture, although the number of episodes with resistant nonalbicans species and susceptible C. albicans was small. Howcases of OPC dose-dependent clinical responses occur [18] . Recently, the NCCLS has reported a study on interpreting ever, persistence of infection for ú2 weeks suggests the presence of resistant yeasts, with clinical implications of increasing MICs of fluconazole associated with clinical resistance [18] . Recommended susceptibility breakpoints are an MIC of the fluconazole dose for clinical response. It may also be reasonable to consider persistence of infection as an indication £8 mg/mL as susceptible, an MIC of 16 -32 mg/mL as susceptible but dose-dependent, and an MIC of §64 mg/mL as resistant that susceptibility testing may be warranted. Another finding of our study suggests that the goal of sterile [18] . In this study, an MIC of 16 mg/mL was used because clinical resistance may occur with 100 mg/d, a dosage comcultures during therapy for OPC in HIV-infected patients may not be clinically useful in preventing or delaying relapses durmonly employed for treatment of OPC.
Risk factors for the development of fluconazole-resistant isoing intermittent therapy with fluconazole. It should also be emphasized that sterile cultures were achieved only in one-half lates causing OPC in HIV-infected patients include advanced immunosuppression, indicated by low CD4 cell counts, and of the episodes, even those with very susceptible isolates. In addition, a sterile culture was not a consistent outcome of prior fluconazole use [6, 9, 10, 13] . In addition, total use of ú10 g of fluconazole has been significantly associated with treatment, even for the same patient for whom MICs were stable. Sterile cultures at the end of therapy were unlikely in the development of resistance [10, 13] .
In our experience with late-stage HIV infection, we noted episodes with yeast isolates for which cultures revealed MICs of §8 mg/mL. a high prevalence of resistant yeasts by using chromogenic media with fluconazole for screening cultures; this finding In summary, fluconazole at daily doses of up to 800 mg is highly effective therapy for OPC in HIV-infected patients, even was confirmed with NCCLS macrobroth testing. Despite the frequent isolation of yeasts for which MICs were §16 in cases where yeast isolates with decreased susceptibility to fluconazole are present. There is a strong correlation with the mg/mL, almost all patients responded clinically to fluconazole at daily doses of up to 800 mg. The presence of resistant presence of resistant isolates as determined with NCCLS methodology and the requirement of higher doses of fluconazole isolates did not significantly affect the severity of symptoms or the extent of lesions at initial presentation. However, there for clinical resolution of OPC. Clinical symptoms do not appear to be affected by the presence of resistant isolates, although was a trend toward more severe disease with the presence of resistant isolates.
there may be a trend toward moderate to severe disease being more common in cases where resistant isolates are present. Clinical resistance leading to failure of 800 mg of fluconazole/d was rare, seen in only four (2.6%) of 155 episodes.
Finally, microbiological response may not be important in determining the time to relapse after successful treatment with In all four of these episodes, isolates for which MICs of fluconazole were §64 mg/mL were recovered. Although sevfluconazole.
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